Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
Bio-Path Holdings presented interim results from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for treating acute myeloid leukemia (AML) at the 2024 European Hematology Association Congress.
Dr. Jorge Cortes presented data showing the combination therapy was well-tolerated and demonstrated significant clinical improvements. In Cohort 1, 75% of evaluable newly diagnosed AML patients achieved complete remission (CR), CR with partial recovery (CRh), or CR with incomplete hematologic recovery (CRi). In Cohort 2, 55% of evaluable relapsed/refractory AML patients achieved CR/CRi/CRh. Adverse events included fatigue, anemia, and neutropenia, with severe events like febrile neutropenia and sepsis. Bio-Path plans to continue enrolling up to 98 and 54 patients for Cohorts 1 and 2 respectively.
- 75% of evaluable newly diagnosed AML patients achieved CR, CRh, or CRi.
- 55% of evaluable relapsed/refractory AML patients achieved CR, CRh, or CRi.
- Prexigebersen combination therapy demonstrated a tolerable safety profile.
- Data presented at a prestigious international conference, enhancing global recognition.
- Continued enrollment planned, indicating confidence in the trial's progress.
- High frequency of adverse events, including fatigue (72%), anemia (60%), and neutropenia (49%).
- Severe adverse events like febrile neutropenia (26%) and sepsis (5%) were reported.
- Only a partial response or stable disease in some patients lowers overall efficacy rates.
Insights
The interim data from Bio-Path Holdings’ Phase 2 study of prexigebersen for the treatment of acute myeloid leukemia (AML) demonstrates significant clinical improvement in both newly diagnosed and relapsed/refractory patient cohorts. Particularly noteworthy is the high rate of complete remission (CR), with
From a clinical perspective, the tolerability profile is encouraging, with adverse events aligning with the expected side effects of decitabine and venetoclax. The frequent severe adverse events like febrile neutropenia and sepsis warrant close monitoring but do not overshadow the potential benefits observed in the treatment efficacy.
For investors in the biotechnology sector, these results indicate that prexigebersen could become a viable addition to the arsenal of AML therapies, particularly given the unmet need for effective treatments in this high-risk patient group. The continuation of patient enrollment suggests confidence in the drug's prospects and underscores the need for further validation through larger patient samples.
The positive interim results from Bio-Path Holdings’ Phase 2 study hold significant implications for the company’s financial health and future prospects. Achieving high rates of complete remission in both newly diagnosed and relapsed/refractory AML patients positions prexigebersen as a strong candidate for eventual FDA approval and market entry. This could lead to substantial revenue streams, enhancing shareholder value.
Investors should consider the potential market size for AML treatments. Acute myeloid leukemia has a notably high unmet need and successful commercialization of prexigebersen could capture a significant market share. The ongoing trials and continued enrollment highlight Bio-Path’s strategic commitment to establishing robust clinical data, which is critical for regulatory success and subsequent market penetration.
Furthermore, the positive safety profile, despite the usual severe adverse events associated with AML therapy, reduces the risk of regulatory hurdles related to safety concerns. Prospective investors should monitor upcoming data releases and regulatory milestones, as these will be pivotal in driving stock performance.
Overall, these developments appear favorable for Bio-Path’s market positioning and long-term growth potential.
The latest data from Bio-Path Holdings’ Phase 2 trial of prexigebersen underscores the therapeutic potential of DNAbilize® liposomal delivery and antisense technology in the oncology market. The significant clinical improvements observed in AML patients support the efficacy of this approach, which could revolutionize the treatment landscape for blood cancers.
For investors, this news indicates a strong market opportunity. The continued enrollment in the study signals ongoing progress and confidence in the drug's potential. Moreover, the presentation at the European Hematology Association Congress enhances Bio-Path’s visibility within the global medical community and could attract strategic partnerships or licensing deals, further bolstering the company's market position.
The emphasis on compelling interim results and a tolerable safety profile aligns with industry trends favoring targeted therapies with manageable side effects. This positions Bio-Path well against competitors in the oncology space. Investors should anticipate potential strategic moves by Bio-Path to capitalize on these promising results, including collaborations and potential market expansion.
Overall, the market dynamics appear favorable and these findings reinforce Bio-Path’s competitive edge in developing innovative cancer therapies.
Encore Presentation Highlights Positive Results from Interim Analysis Demonstrating Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients
HOUSTON, June 14, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, presented interim results from the Company’s Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML) in a poster presentation at 2024 European Hematology Association (EHA) Congress, on June 14, 2024 in Madrid, Spain.
Jorge Cortes, M.D., Director of the Georgia Cancer Center, presented data showing prexigebersen continues to be well-tolerated and has now demonstrated compelling efficacy results in two reporting cohorts including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, both of which exceeded outcomes with frontline therapy.
“It was a pleasure to present these compelling data to an audience of European oncologists who treat AML patients and understand the continued great need for new therapeutic options,” said Peter Nielsen, Chief Executive Officer of Bio-Path. “Given that our study is being conducted in the U.S., this encore presentation is an important step towards educating global oncology leaders on the benefits of prexigebersen and its potential to be another tool in their fight against AML.”
Data Highlights
In Cohort 1, 31 newly diagnosed patients were enrolled; 20 evaluable patients (9 male:
In Cohort 2, 38 relapsed/refractory patients were enrolled; 23 evaluable patients (13 male:
Among the evaluable patients of both cohorts, adverse events were consistent with those expected with decitabine and venetoclax and/or AML, including fatigue (
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1/1b study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.
For more information, please visit the Company's website at www.biopathholdings.com.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These statements are based on management's current expectations and accordingly are subject to uncertainty and changes in circumstances. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Bio-Path’s ability to raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, the timing of enrollment and release of data in such clinical studies, the accuracy of such data, limited patient populations of early stage clinical studies and the possibility that results from later stage clinical trials with much larger patient populations may not be consistent with earlier stage clinical trials, its ability to obtain domestic and/or foreign regulatory approval for its drug candidates, the maintenance of intellectual property rights, that patents relating to existing or future patent applications will be issued or that any issued patents will provide meaningful protection of our drug candidates, the impact, risks and uncertainties related to global pandemics, including the COVID-19 pandemic, and actions taken by governmental authorities or others in connection therewith, and such other risks which are identified in Bio-Path's most recent Annual Report on Form 10-K, in any subsequent quarterly reports on Form 10-Q and in other reports that Bio-Path files with the Securities and Exchange Commission from time to time. These documents are available on request from Bio-Path Holdings or at www.sec.gov. Bio-Path disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information:
Investors
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
FAQ
What are the results from Bio-Path's Phase 2 study of prexigebersen?
What adverse events were noted in the prexigebersen Phase 2 study?
How many patients are Bio-Path planning to enroll in the Phase 2 prexigebersen study?
Where were the interim results of the prexigebersen study presented?
What is the significance of prexigebersen for Bio-Path Holdings?
